scholarly article | Q13442814 |
P50 | author | Marianne Manchester | Q55190308 |
R. John Collier | Q2123854 | ||
P2093 | author name string | Giuseppe Destito | |
John A T Young | |||
Diane Thomas | |||
Heather M Scobie | |||
Darran J Wigelsworth | |||
John M Marlett | |||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1047-1051 | |
P577 | publication date | 2005-08-10 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | A soluble receptor decoy protects rats against anthrax lethal toxin challenge | |
P478 | volume | 192 |
Q39958178 | A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax |
Q39124815 | A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro. |
Q34102678 | A receptor-based switch that regulates anthrax toxin pore formation |
Q28469319 | A viral nanoparticle with dual function as an anthrax antitoxin and vaccine |
Q33380169 | Anthrax edema toxin modulates PKA- and CREB-dependent signaling in two phases. |
Q38060730 | Anthrax lethal toxin and the induction of CD4 T cell immunity |
Q30481474 | Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature |
Q30830672 | Anthrax toxin receptor 2 determinants that dictate the pH threshold of toxin pore formation |
Q27304959 | Anthrax toxin receptor 2 functions in ECM homeostasis of the murine reproductive tract and promotes MMP activity |
Q34128041 | Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis |
Q28572283 | Anthrax toxin receptor 2-dependent lethal toxin killing in vivo |
Q38132268 | Anthrax vaccines: present status and future prospects. |
Q37404847 | Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis |
Q37262118 | Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax |
Q38760476 | Anti-virulence Strategies to Target Bacterial Infections |
Q37676924 | Anti-virulence strategies to combat bacteria-mediated disease |
Q33506611 | Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy |
Q36895609 | Bacillus anthracis: interactions with the host and establishment of inhalational anthrax. |
Q39011436 | Bidirectional effect of Wnt signaling antagonist DKK1 on the modulation of anthrax toxin uptake. |
Q39355381 | Changing the receptor specificity of anthrax toxin |
Q36761999 | Characterization of the interaction between anthrax toxin and its cellular receptors |
Q42363492 | Constitutive MEK1 Activation Rescues Anthrax Lethal Toxin-Induced Vascular Effects In Vivo |
Q40249153 | Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1. |
Q41114190 | Defensive strategies of Bacillus anthracis that promote a fatal disease |
Q28730606 | Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment |
Q33267360 | Divalent metal ion coordination by residue T118 of anthrax toxin receptor 2 is not essential for protective antigen binding |
Q37115804 | Efficient neutralization of antibody-resistant forms of anthrax toxin by a soluble receptor decoy inhibitor |
Q40395310 | Expression, Purification, and Biophysical Characterization of a Secreted Anthrax Decoy Fusion Protein in Nicotiana benthamiana |
Q38355454 | Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor |
Q34100366 | Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin |
Q33557833 | Identification of a claudin-4 residue important for mediating the host cell binding and action of Clostridium perfringens enterotoxin |
Q30559245 | Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay. |
Q35436076 | Imaging tumor endothelial marker 8 using an 18F-labeled peptide |
Q34015820 | Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design |
Q90225928 | Inhibition of Pore-Forming Proteins |
Q64255131 | Inhibition of bacterial toxin recognition of membrane components as an anti-virulence strategy |
Q35987872 | Inhibitors of the Metalloproteinase Anthrax Lethal Factor |
Q37314633 | Molecular decoys: antidotes, therapeutics and immunomodulators |
Q40130027 | Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists |
Q34659076 | Receptors of anthrax toxin and cell entry. |
Q36507229 | Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor |
Q33258307 | Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine |
Q26775093 | Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane Insertion and Pore Formation |
Q36864660 | Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells |
Q58091462 | Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus |
Q37996325 | Targeting bacterial toxins |
Q34732577 | Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy |
Q42397574 | The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, "Bacillus-ACT05". |
Q27662859 | The Structure of Tumor Endothelial Marker 8 (TEM8) Extracellular Domain and Implications for Its Receptor Function for Recognizing Anthrax Toxin |
Q41954911 | Toxicity of anthrax toxin is influenced by receptor expression |
Q35985908 | Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore |
Q33933081 | Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors |
Q46720421 | Whole-cell voltage clamp measurements of anthrax toxin pore current |
Q61797224 | Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic? |
Search more.